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Summary
Biomarkers are tumour- or host-related factors that correlate with tumour biological 
behaviour and patient prognosis. Modern analytical techniques have identified numero-
us possible biomarkers, but their relevance to melanoma progression, clinical outcome 
and the selection of optimal treatment strategies still needs to be established. In this 
review, we discuss common predictive biomarkers of melanoma. 
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Malignant melanoma is one of the most aggressive malignancies in hu-
man and is responsible for almost 60% of lethal skin tumors. Its incidence 
has been increasing in white population in the past two decades.  Melanoma 
metastasizes quickly and only 14% of patients with metastatic disease can 
expect to live for 5 years [1,2]. 
Melanoma is a very enigmatic and heterogeneous cancer. There is a com-
plex interaction of environmental and endogenous, including genetic, risk 
factors in developing malignant melanoma [3]. Deregulation in oncogenes 
and tumour suppressors, as well as multiple molecular signals, are requi-
red for melanoma initiation and progression, leading to a range of interac-
ting pathways. Attempts are ongoing to unravel this complex network, thus 
allowing the identification of novel genetic and molecular biomarkers, as 
well as potential therapeutic targets [4]. 
Current prognostic markers based on the conventional American Joint 
Committee on Cancer (AJCC) staging system (TNM) are Breslow tumour 
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thickness, presence of ulceration, mitotic count and extent of nodal involve-
ment for primary cutaneous melanoma, as well as serum lactate dehydroge-
nase (LDH) and site of metastases for distant metastatic disease [1,5].
Biomarkers are tumour or host related factors that correlate with tumour 
biological behaviour and patient prognosis. In a very general sense, a bio-
marker describes any measurable diagnostic indicator that is used to assess 
the risk or presence of disease. Although longstanding, the quest to identify 
relevant and useful biomarkers for cutaneous melanoma, assessed by either 
serum or immunohistochemistry, has yielded few results. Biomarkers in me-
lanoma may serve a variety of purposes, they may serve as a surrogate for 
identifying present disease burden, as with lactate dehydrogenase (LDH), 
identifying patients with more aggressive disease, and/or determining dise-
ase responsiveness to various therapies [4,5,6]. 
An explosion of molecular information over the years has unveiled an 
array of candidate biomarkers for enhanced prognosis and outcome predic-
tion. More than 100 studies have published experiments using DNA micro-
arrays to investigate
the gene expression profiles found in melanoma. Most expression studi-
es designed to investigate the molecular mechanisms associated with mela-
noma progression used melanoma cell lines or metastatic tumour samples. 
Although many candidates have been reported, few have proven reliability 
or predictability at present to allow for routine use. Serum biomarkers are 
assessed by the peripheral blood, whereas immunohistochemical biomar-
kers may be evaluated on formalin-fixed paraffin-embedded tissue [7].
Modern personalised medicine intends to use individual molecular mar-
kers and patterns of markers to subdivide traditional tumour stages into su-
bsets that behave differently from each other. 
As early as in 1954, increased levels of LDH (Lactate dehydrogenase) were 
detected in serum of melanoma patients ever since, the value of LDH as a 
tumour marker for malignant melanoma has been discussed. LDH is of me-
dical significance because it is found extensively in body tissues, such as 
blood cells and heart muscle. Because it is released during tissue damage, it 
is a marker of common injuries and disease [8]. 
LDH was reported to be an indicator for liver metastases, with a respec-
tive sensitivity and specificity of 95% and 83% in stage II patients, and 87% 
and 57% in stage III patients. Patients with abnormal LDH levels had a si-
gnificantly decreased survival. Taken together, increasing evidence exists to 
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demonstrate that LDH is elevated in advanced disease, predominantly in 
cases with liver metastases. LDH might serve as a prognostic factor in late-
stage malignant melanoma. This has been discussed in a study where LDH 
was evaluated in combination with other tumour markers such as S100B and 
MIA and identified, by multiple logistic regression analysis, as the only stati-
stically significant marker for disease progression. LDH has been included in 
the AJCC staging system, and patients with distant metastases and elevated 
LDH are considered stage IV M1c [9,10].
The best-studied melanoma biomarker is currently S100B. First descri-
bed in 1980 in cultured melanoma cells, S100B has quickly become a well-
established and widely used immunohistochemical marker of pigmented 
skin lesions. S-100B protein is a 21-kd thermo-labile acidic dimeric protein 
consisting of two beta subunits, which was originally isolated from the CNS 
[11]. In 1995, a first study was published evaluating the clinical significance of 
serum S100B in melanoma. The study showed that observed death ratio was 
markedly increased with increasing concentrations of S100B (P < 0.001). In 
other studies, baseline serum S100B protein concentrations correlated with 
prognosis and stage, rising concentrations of serum S100B indicated progre-
ssion of the disease and complete decline in serum S100B concentrations re-
flected remission [12,13]. 
Although determination of serum biomarkers such as LDH and S100B 
may have a prognostic value, it does not translate into an adequate thera-
peutic intervention and survival benefit due to limited  efficacy of current 
treatment options in advanced melanomas. 
MIA (Melanoma-inhibiting activity) was identified in the early 1990s as a 
soluble 11 kDa protein with growth-inhibiting activities secreted from mali-
gnant melanoma cells. The fact that it was strongly expressed in malignant 
melanocytic tumours, but not in benign human skin melanocytes or benign 
melanocytic nevi, indicated that MIA may represent a novel tumour marker 
for malignant melanoma [14,15]. 
TA90-IC (Tumour-associated antigen 90 immune complex) is a 90kD glyco-
protein found in the serum and urine of 63% to 68% patients with  mela-
noma. Since TA90 binds to endogenous anti TA90 monoclonal antibody 
immune complex (TA90-IC) may be detected in the serum of patients with 
melanomom by ELISA assay. Multivariate regression analysis revealed that 
TA90IC was an independent predictor of survival when elevation occurred 
between 2 weeks and 3 months, whereas MIA was an independent predictor 
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appearing at 4–6 months. In general, elevation of TA90IC preceded increase 
of MIA in patients who developed recurrence. Additional studies in popu-
lations not receiving vaccines will further clarify the clinical utility of these 
assays [16,17].
YKL-40 is a heparin- and chitin-binding lectin secreted by activated ne-
utrophils and macrophages during the late stages of differentiation, but also 
by arthritic chondrocytes, differentiated vascular smooth muscle cells and 
fibroblast-like synovial cells. Elevated serum levels of YKL-40 are seen in a 
number of non- malignant diseases characterised by inflammation and re-
modelling of the extracellular matrix, and were shown to be an independent 
prognostic factor for poor survival in patients with cancer of the breast, co-
lon, ovary, kidney and lung. Study analysis showed that serum YKL- 40 (P 
= 0.004) and serum LDH (P = 0.004) were independent prognostic factors for 
survival. A combination variable of elevated serum YKL-40 and LDH qua-
drupled the risk of early death (P < 0.001) compared with that of patients with 
normal levels of the markers. The use of serum YKL-40 has not received Food 
and Drug Administration approval for use as a biomarker for cancer [18,19].
Melanoma is a complex genetic disease, and multiple genetic alterations 
have been reported to play a role during disease progression. The mitogen-
activated protein (MAP) kinase pathway is an important driver in melanoma 
and is made up of several potential targets providing therapeutic options. 
In this pathway, the activation of RAS proteins stimulates the RAF kinases 
ARAF, BRAF, and RAF1. This process causes phosphorylation of the MEK ki-
nases, which phosphorylate the ERK kinases. Activated ERK regulates cyclin 
D1, which, in turn, regulates multiple cellular processes involved in cell divi-
sion. Dysregulation of BRAF signaling has been shown to be one of these key 
drivers of the disease [20,21].
In 2002, Davies et al. first reported that BRAF is mutated in approximately 
8% of human tumors, most frequently in melanoma where the BRAFV600 mu-
tation is observed in approximately 50% of tumors. Mutations in BRAFV600E 
may cause the protein to become oncogenic. In preclinical studies, oncogenic 
BRAF signaling that is a result of this mutation may lead to increased and 
uncontrolled cell proliferation and resistance to apoptosis (programmed cell 
death) [22].
Drugs that treat cancers driven by BRAF have been developed. Two of 
these drugs, vemurafenib and dabrafenib are approved by FDA for treatment 
of late-stage melanoma. Vemurafenib (PLX4032) was the first drug to come 
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Figure 1. Metastatic melanoma positive with BRAF V600E (dot-like cytoplasmatic 
positivity X200).
out of fragment-based drug discovery. BRAF V600E mutations are associated 
with increased sensitivity to BRAF inhibitors [23].  
The novel BRAF V600E mutant-specific antibody, VE1 is currentlly used 
to detect the presence of the BRAF V600E mutation in patients with meta-
static melanoma on paraffin-embedded, formalin-fixed melanoma biopsies. 
The antibody had a sensitivity of 97% and a specificity of 98% for detecting 
the presence of  BRAF in immunohistochemical (IHC) analysis (Figures 1, 2). 
Clinical use of the V600E BRAF antibody should be a valuable supplement to 
conventional mutation testing and allow V600E mutant metastatic melano-
ma patients to be triaged rapidly into appropriate treatment pathways [24].
Since the discovery of BRAFV600E mutations in melanoma in 2002, scienti-
sts and clinicians have learned much about the role of mutated BRAFV600E, but 
many questions remain unanswered and research is ongoing. The rapidly 
increasing incidence of melanoma, coupled with its highly aggressive meta-
static nature and limited current treatment options, make this an active and 
exciting area of research.
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Current molecular information indicates that melanoma should be viewed 
as a heterogeneous group of disorders with molecularly distinct defects in 
important cellular processes that include cell cycle regulation, cell signalling, 
cell adhesion, cell differentiation and cell death. The heterogeneity of these 
molecular signatures has two important implications: first, it accentuates the 
need for individualisation of melanoma diagnosis, prognosis and treatment; 
and second, it provides an array of potential biomarkers and novel putative 
drug targets to attain this individualisation. Careful dissection of melanoma 
into more homogeneous subgroups may be essential for identification of tre-
atment benefits in specific subcategories of patient. At present, only LDH has 
been included in the AJCC staging system, no identified potential biomarker 
has undergone a large, rigorous, prospective trial with multivariate analysis 
that would allow it to be fully validated and developed for clinical practice. 
As such, there still remains an acute need for such markers in melanoma [25]. 
Figure 2. Metastatic melanoma in lymph node positive with BRAF V600E (dot-like 
cytoplasmic positivity X400).
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Sažetak
Prognostički biomarkeri melanoma kože
Biomarkeri su faktori vezani za tumor ili domaćina koji koreliraju s biološkim pona-
šenjem tumora ili prognozom bolesnika. Moderne analitičke tehnike su dosada otkrile 
brojne moguće biomarkere, ali njihova važnost u razvoju i progresiji melanoma kože 
kao i kliničkom ishodu bolesti i odabiru najbolje terapije tek se treba utvrditi. U ovom 
preglednom članku navedeni su najčešće korišteni biomarkeri melanoma kože. 
Ključne riječi: biomarkeri; melanom kože; prognoza.
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